Literature DB >> 7201982

Current estimates of the incidence of steroid responsive idiopathic nephrosis in Kentucky children 1-9 years of age.

R J Wyatt, M B Marx, M Kazee, N H Holland.   

Abstract

A review of the medical literature relating to childhood nephrosis revealed no surveys conducted since 1968 which either substantiated or refuted the range in incidence rates reported in earlier studies. Those rates ranged from 1.3 to 2.5 new cases per year among 100,000 white and non-white children under 10 years of age. The present report documents the incidence of steroid responsive idiopathic nephrosis in the eastern part of Kentucky during the years 1970 through 1979. The overall rate of 1.8 new cases per year was similar to that described in previous reports. A suggestion of an increased rural vs urban incidence was noted.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7201982

Source DB:  PubMed          Journal:  Int J Pediatr Nephrol        ISSN: 0391-6510


  4 in total

1.  Estimation of childhood nephrotic syndrome incidence: data from the atlanta metropolitan statistical area and meta-analysis of worldwide cases.

Authors:  Jackson Londeree; Courtney E McCracken; Larry A Greenbaum; Evan J Anderson; Laura C Plantinga; Scott E Gillespie; Chia-Shi Wang
Journal:  J Nephrol       Date:  2021-07-02       Impact factor: 3.902

Review 2.  Nephrotic syndrome in The Netherlands: a population-based cohort study and a review of the literature.

Authors:  Loubna El Bakkali; Robert Rodrigues Pereira; Dirk J Kuik; Johannes C F Ket; Joanna A E van Wijk
Journal:  Pediatr Nephrol       Date:  2011-05-01       Impact factor: 3.714

Review 3.  Primary coenzyme Q10 nephropathy, a potentially treatable form of steroid-resistant nephrotic syndrome.

Authors:  Weizhen Tan; Rannar Airik
Journal:  Pediatr Nephrol       Date:  2021-01-22       Impact factor: 3.714

Review 4.  Ethnic Differences in Childhood Nephrotic Syndrome.

Authors:  Rahul Chanchlani; Rulan S Parekh
Journal:  Front Pediatr       Date:  2016-04-19       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.